Hedges Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.19M	Buy	22,775 +275	+1%	+$16.5K	0.84%	43
2025 Q3	$1.46M	Sell	22,500 -2,200	-9%	-$126K	1.12%	29
2025 Q2	$1.2M	Sell	24,700 -4,650	-16%	-$180K	0.97%	36
2025 Q1	$999K	Buy	29,350 +5,000	+21%	+$212K	0.66%	56
2024 Q4	$958K	Buy	24,350 +1,200	+5%	+$56.7K	0.63%	55
2024 Q3	$1.09M	Buy	23,150 +1,350	+6%	+$68.5K	0.72%	49
2024 Q2	$1.18M	Buy	21,800 +2,425	+13%	+$140K	0.85%	42
2024 Q1	$1.32M	Sell	19,375 -2,000	-9%	-$143K	0.93%	39
2023 Q4	$1.34M	Sell	21,375 -1,150	-5%	-$63.6K	1.05%	33
2023 Q3	$1.02M	Buy	22,525 +3,575	+19%	+$185K	0.89%	37
2023 Q2	$1.06M	Buy	18,950 +2,650	+16%	+$150K	0.9%	37
2023 Q1	$737K	Buy	16,300 +625	+4%	+$30.4K	0.63%	48
2022 Q4	$637K	Buy	15,675 +5,200	+50%	+$276K	0.57%	47
2022 Q3	$685K	Sell	10,475 -1,900	-15%	-$138K	0.68%	46
2022 Q2	$753K	Buy	12,375 +2,600	+27%	+$153K	0.71%	43
2022 Q1	$614K	Buy	9,775 +1,425	+17%	+$89.5K	0.48%	61
2021 Q4	$633K	Buy	+8,350	New	+$729K	0.49%	60